52
E. Kraut
Institute: a report of 979 patients. J Clin Oncol 1998;16: 3007–3015.
13. RobakT,Blasinkra-MorawiccM,Blonski J, et al. 2-Chlo- rodeoxyadenosine inthe treatment of hairy cell leukemia andhairy cell leukemia variant. Eur J Haemtol 1999; 62:49–56.
14. Tallman MS, Hakimian D, Variakojiis D, et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80:2203–2209.
15. Smith JW, Longo DL, Urba WJ, et al. Prolonged continuous treatment of hairy cell leukemia patients with recombinant interferon-a-2a. Blood 1991;78:1664–1671.
16. Benz R, Siciliano RD, Stussi G, Fehr J. Long term followup of interferon-alpha induction and low dosemaintenance therapy in hairy cell leukemia. Eur J Haematol 2009;82:194–198.
17. Damasio EE, Clavio M, Masoudi B, et al. Alpha interferon as induction and maintenance therapy in hairy cell leukemia. Eur J Haemtol 2000;64:47–52.
18. Nieva J, Bethel K, Saven A. Phase II study of rituximab in the treatment of cladribine failed patients with hairy cell leukemia. Blood 2003;102:810–813.
19. Thomas D, O’Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102: 3906–3911.
20. Hagberg H, Lundholm L. Rituximab, a chimaeric anti CD20 monoclonal antibody in the treatment of hairy cell leukemia Br J Haematol 2001;115:609–611.
21. Else M, Ruchlemer R, Osuji N, et al. Long remissions in patients with hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer 2005;104:2442–2448.
22. Huynh E, Sigal D, Saven A. Cladribine in the treatment of hairy cell leukemia: initial and subsequent results Leuk Lymphoma 2009;50:12–17.
23. Flinn IW, Kopecky KJ, Foucar KM, et al. Long-term follow- up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000;96:2981–2986.
24. Habermann TM, Anderson JW, Cassileth PA, et al. Sequen- tial administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol 1992;80:466–471.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122